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Abstract
Both ornithine decarboxylase (ODC) and its regulatory protein, antizyme inhibitor (AZI), can bind with antizyme (AZ), but the
latter has a higher AZ-binding affinity. The results of this study clearly identify the critical amino acid residues governing the
difference in AZ-binding affinities between human ODC and AZI. Inhibition experiments using a series of ODC mutants
suggested that residues 125 and 140 may be the key residues responsible for the differential AZ-binding affinities. The
ODC_N125K/M140K double mutant demonstrated a significant inhibition by AZ, and the IC50 value of this mutant was
0.08 mM, three-fold smaller than that of ODC_WT. Furthermore, the activity of the AZ-inhibited ODC_N125K/M140K enzyme
was hardly rescued by AZI. The dissociation constant (Kd) of the [ODC_N125K/M140K]-AZ heterodimer was approximately
0.02 mM, which is smaller than that of WT_ODC by approximately 10-fold and is very close to the Kd value of AZI_WT,
suggesting that ODC_N125K/M140K has an AZ-binding affinity higher than that of ODC_WT and similar to that of AZI. The
efficiency of the AZI_K125N/K140M double mutant in the rescue of AZ-inhibited ODC enzyme activity was less than that of
AZI_WT. The Kd value of [AZI_K125N/K140M]-AZ was 0.18 mM, nine-fold larger than that of AZI_WT and close to the Kd value
of ODC_WT, suggesting that AZI_K125N/K140M has an AZ-binding affinity lower than that of AZI_WT and similar to that of
ODC. These data support the hypothesis that the differences in residues 125 and 140 in ODC and AZI are responsible for the
differential AZ-binding affinities.
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Introduction
Ornithine decarboxylase (ODC, EC 4.1.1.17) is the first and
rate-limiting enzyme in polyamine biosynthesis [1,2], which is
essential for cell growth and differentiation in eukaryotes [3–6].
This enzyme catalyzes the pyridoxal 5-phosphate (PLP)-dependent
decarboxylation of ornithine to putrescine [1,2,5]. ODC and
polyamines participate in many important biological processes,
including cell proliferation, differentiation, embryonic develop-
ment, cell cycle, and apoptosis [3,6–12]. The in vivo regulation of
ODC is very important for the control of cell proliferation [6].
High levels of ODC and polyamines are associated with several
human diseases and diverse cancers [6,9,13–20], and the enzyme
activity is related to the beginning and successive development of
neoplastic diseases [9,18–20]. Therefore, ODC has been recog-
nized as an oncogenic enzyme, and the study of enzyme inhibitors
of ODC may be helpful in the development of therapeutic drugs
for the treatment of many cancers [6,21].
The in vivo regulation of ODC is unique [22]. The regulatory
protein antizyme (AZ), the expression of which is induced by
increased polyamine concentrations, takes charge of ODC
inhibition and degradation [23,24]. ODC undergoes ubiquitin-
independent proteasomal degradation by directly interacting with
AZ [25–27]. The binding of AZ to ODC promotes the dissociation
of the ODC dimer. The AZ monomer binds to the ODC dimer to
form an inactive ODC-AZ heterodimer that is targeted for
degradation by the 26S proteasome [1,24,28–32]. There is a
feedback mechanism for the control of ODC levels. When the
level of polyamines is elevated, antizymes are overexpressed to
inhibit ODC enzyme activity and to promote the proteolytic
degradation of ODC [24,27,28]. Thus, AZ acts as a negative
regulator of polyamine metabolism by suppressing ODC enzyme
activity and polyamine transport to restrict polyamine concentra-
tions [1,24,28,33]. Because high ODC activity is associated with
the majority of human malignancies [20], AZ is considered to
function as a tumor suppressor.
Another regulatory protein involved in the regulation of ODC is
antizyme inhibitor (AZI, [34]) AZI is homologous to ODC but
lacks decarboxylase activity [29]. AZI binds to AZ with a higher
affinity than does ODC and thus rescues ODC from the ODC-AZ
complex to recover ODC enzyme activity [29,35,36]. Unlike
ODC, both the AZI and AZ proteins undergo ubiquitin-
dependent degradation within several minutes to one hour
[28,37]. Furthermore, the binding of AZ to AZI suppresses the
ubiquitination of AZI, thus inhibiting its degradation [37,38]. In
contrast to AZ, AZI is a positive regulator of ODC that inactivates
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and prevents the proteolytic degradation of ODC. Thus, AZI may
be oncogenic and may play a role in tumor progression [34].
Overexpression of AZI has been demonstrated to enhance cell
proliferation and stimulate cell transformation [34,40,41]. More-
over, down-regulation of AZI inhibits cell proliferation and
decreases ODC activity through the up-regulation of AZ function
[42]. These results reveal that AZI is a positive modulator for cell
proliferation and tumorigenesis.
ODC and AZI are homologous proteins with high sequence
identity and structure similarity. ODC is a homodimer containing
461 amino acid residues in each monomer with a molecular
weight of 106 kDa [43]. ODC activity requires dimer formation
because the active site in each monomer is formed by the interface
between the N-terminus of one monomer and the C-terminus of
the other subunit [43–47]. AZI is a monomer under physiological
conditions [48]; it contains 448 amino acid residues and has a
molecular weight of 50 kDa. AZI binds more tightly to AZ than
does ODC [29,37]. A structural study of human ODC and mouse
AZI has suggested that the region from residue 117 to residue 140
may be the putative AZ-binding site [44,48]. Furthermore, the
docking structures of the mouse AZ-ODC and AZ-AZI complexes
suggest that ODC and AZI may occupy the same binding site on
AZ [49]. In the present work, we identified the critical amino acid
residues governing the difference in AZ-binding affinity between
ODC and AZI. Sequence alignments of human ODC and AZI in
the putative AZ-binding site, between amino acids 117 and 140,
demonstrated that residues 125, 126, 133, 135 and 140 are not
conserved between ODC and AZI (Figure 1A). In this study, site-
directed mutagenesis was used to generate a series of mutants of
ODC and AZI. According to the size-distribution analysis of these
ODC and AZI mutants, we have demonstrated that residues 125
and 140 are responsible for the differential AZ-binding affinities
between ODC and AZI.
Results and Discussion
The X-ray structure of human ODC suggests that the putative
binding site of AZ may be located between amino acids 117 and
140 of ODC [44]. Modeled structures of the ODC-AZ and AZI-
AZ complexes also suggest that both ODC and AZI bind to the
same binding site on AZ [49]. Although the structures of ODC
and AZI are very similar and may have the same AZ-binding site
(Figure 1, A and B), AZI binds to AZ more tightly than does ODC
[29]. Sequence alignment of amino acids 117 and 140 in human
ODC and AZI revealed that all amino acid residues are conserved
with the exceptions of residues 125, 126, 133, 135 and 140
(Figure 1A). These non-conserved amino acid residues may be the
factors governing the differential AZ-binding affinities between
ODC and AZI. To address the question, these amino acid residues
in human ODC were individually changed to the residues present
in human AZI. Similarly, the corresponding amino acid residue in
human AZI was substituted into human ODC.
Figure 1. Sequence alignment and structures of ODC and AZI. (A) Pairwise sequence alignment between ODC and AZI in the putative AZ-
binding element. (B) Structure of human ODC monomer (PDB code: 1D7K). (C) Structure of mouse AZI monomer (PDB code: 3BTN). The putative AZ-
binding site in ODC is colored in deep green and that in AZI is colored in hot pink. This figure was generated with PyMOL (DeLano Scientific LLC, San
Carlos, CA, USA).
doi:10.1371/journal.pone.0019253.g001
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We first mutated these five residues to create a series of single
mutants of ODC: ODC_N125K, ODC_N126V, ODC_F133C,
ODC_S135N and ODC_M140K. For ODC_WT, the enzyme
activity was gradually inhibited by the increased concentrations of
AZ (Figure 2, closed circles), and the concentration of AZ required
for 50% inhibition of ODC enzyme activity (IC50,AZ) was
approximately 0.25 mM (Table 1). ODC_N125K was inhibited
more obviously than ODC_WT (Figure 2A, open circles), with an
IC50,AZ value of 0.1 mM (Table 1). The ODC_N126V,
ODC_F133C and ODC_S135N enzymes were less sensitive to
AZ inhibition (Figure 2, B, C and D, respectively, open circles); the
IC50,AZ values of these mutant enzymes were 0.44, 0.45 and
0.49 mM, respectively, all slightly larger than that of ODC_WT
(Table 1). The ODC_M140K enzyme, similar to ODC_N125K,
Figure 2. Inhibition of wild-type and mutant ODC enzyme in the presence of AZ. Open circles: ODC_WT; closed circles: mutant ODC
enzyme. (A) ODC_N125K. (B) ODC_N126V. (C) ODC_F133C. (D) ODC_S135N. (E) ODC_M140K. (F) ODC_N125K/M140K. In the inhibition assay, the
enzyme concentration was fixed at 20 mg/mL.
doi:10.1371/journal.pone.0019253.g002
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IC50,AZ value of this mutant was 0.13 mM, smaller than that for
ODC_WT (Table 1). We also constructed the ODC_N125K/
M140K double mutant enzyme. The inhibition of this double
mutant by AZ was even greater than that of either single mutant,
ODC_N125K or ODC_M140K (Figure 2F, open circles); the
IC50 value of ODC_N125K/M140K was 0.08 mM, three-fold
smaller than that of ODC_WT (Table 1).
AZI rescue for the AZ-inhibited wild-type and mutant
ODC enzyme activity
AZI can rescue ODC monomers from AZ-ODC complexes to
restore ODC activity [29]. We examined the effect of AZI on the
rescue of the activity of AZ-inhibited wild-type and mutant ODC.
The ODC enzyme was first preincubated with AZ, keeping the
molar ratio of AZ monomer versus ODC monomer at 4.0. For
ODC_WT, with increasing AZI concentrations, the residual
enzyme activity increased from 20% to over 90%. For
ODC_N125K and ODC_M140K, although the AZ-inhibited
ODC activity could be recovered, the residual enzyme activity
curves of the two mutants were below the curve of ODC_WT
(Figure 3, A and B, respectively, open circles). When the enzyme
activity of ODC-AZ was restored by AZI to nearly 100%, the
activities of ODC_N125K and ODC_M140K were recovered by
approximately 60% to 70% (at 20 mg of AZI). The activity of the
AZ-inhibited ODC_N125K/M140K enzyme activity was hardly
rescued by AZI; even at high concentrations of AZI, the residual
enzyme activity was only 20% (Figure 3C, open circles). The
resistance of ODC_N125K/M140K to rescue by AZI may result
from the tighter binding of this double mutant to AZ as compared
with ODC_WT.
These results for the AZ inhibition and AZI rescue experiments
indicate that the replacement of Asn125 and Met140 in ODC with
the respective amino acid residues, Lys125 and Lys140 that exist
in AZI, results in an ODC enzyme that is more sensitive to AZ
inhibition and more resistant to the rescue by AZI. This
demonstrates the significance of these two residues in determining
the differential AZ-binding affinity between ODC and AZI.
The effect of wild-type and mutant AZI on the rescue of
the activity of AZ-inhibited ODC
We further created the single mutants AZI_K125N and
AZI_K140M and the double mutant AZI_K125N/K140M. To
optimize the rescue of these mutant AZI proteins, the molar ratio
of ODC versus AZ was fixed at 3.5 (Figure 4). For AZI_K125N,
although the AZ-inhibited ODC activity could be restored, the
residual enzyme activity curve of this mutant was below the curve
for AZI_WT (Figure 4A, open circles), indicating that the rescue
efficiency of this AZI mutant was less than that of AZI_WT. Using
AZI_K140M, the AZ-inhibited ODC activity could also be
restored (Figure 4B, open circles). However, the rescue efficiency
of this AZI mutant was just slightly less than that of AZI_WT,
Table 1. Kinetic parameters and IC50 values of the wild-type
and mutant ODC enzymes.
ODC Km,ornithine (mM) kcat (s
21)I C 50,AZ (mM)
*
WT 0.4860.09 7.460.5 0.2560.07
N125K 0.4860.08 6.960.3 0.1060.002
N126V 0.4260.09 5.860.3 0.4460.25
F133C 0.3060.05 4.860.1 0.4560.13
S135N 0.3360.17 5.160.6 0.4960.25
M140K 0.4460.08 6.660.3 0.1360.006
N125K/M140K 0.3460.03 4.460.1 0.0860.015
*All IC50 values were derived from the inhibition curves of ODC in Figure 2.
doi:10.1371/journal.pone.0019253.t001
Figure 3. Rescue of AZ-mediated inhibition of the activity of
wild-type and mutant ODC by AZI. ODC (20 mg/mL) was
preincubated with AZ (34 mg/mL) and was then treated with various
concentrations of AZI. Open circles: ODC_WT; closed circles: mutant
ODC enzyme. (A) ODC_N125K. (B) ODC_M140K. (C) ODC_N125K/
M140K. The molar ratio of AZ monomer versus ODC monomer was fixed
at 4.
doi:10.1371/journal.pone.0019253.g003
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efficiency. The efficiency of the double mutant AZI_K125N/
K140M to rescue the activity of the AZ-inhibited ODC was very
similar to that of AZI_ K125N (Figure 4C, open circles). These
data suggest that these mutations in AZI reduced the efficiency of
the rescue of the activity of AZ-inhibited ODC.
Binding affinity of ODC-AZ and AZI-AZ complex
Size distribution analysis of ODC in the presence of AZ
provided information about the formation of ODC-AZ complexes
(Figure 5A). AZ binds to ODC, which induces the dissociation of
the ODC dimer and results in the formation of an ODC-AZ
heterodimer. AZI can also interact with AZ to form an AZI-AZ
heterodimer [29]. To evaluate the effect of ODC and AZI
mutations on AZ-binding affinity, sedimentation velocity (SV)
experiments with various AZ concentrations were used to
determine the dissociation constants of the ODC-AZ and AZI-
AZ heterodimers (Table 2). Figure 5 shows the size distribution
plots of the WT and mutant ODC and AZI proteins. Without AZ,
ODC existed as a dimer at an S value of approximately 6. When
AZ was present, ODC was dissociated, the dimer peak for ODC
shifted to the left, and the ODC-AZ heterodimer was produced at
an S value of approximately 4.5 (Figure 5A). The Kd value of the
[ODC_WT]-AZ complex was approximately 0.21 mM. For
[ODC_N125K]-AZ and [ODC_M140K]-AZ, the Kd values were
approximately 0.1 mM, two-fold smaller than that of the
[ODC_WT]-AZ complex, suggesting that these two ODC mutant
enzymes had a higher binding affinities for AZ than did the wild
type. The double mutant ODC_N125K/M140K had an AZ-
binding affinity much higher than that of ODC_WT. The Kd
value of the [ODC_N125K/M140K]-AZ heterodimer was
approximately 0.02 mM, smaller than that of WT_ODC by
approximately 10-fold and very close to the Kd value of AZI_WT,
suggesting that ODC_N125K/M140K has an AZ-binding affinity
that is higher than that of ODC_WT and similar to that of AZI.
Thus, ODC_N125K/M140K was more sensitive to AZ inhibition
(Figure 2F) and more resistant to rescue by AZI (Figure 3C).
AZI was present predominately as a monomer at an S value of
approximately 3.6; when AZ was present, the monomeric peak of
AZI shifted to right, and the AZI-AZ heterodimer was formed at
an S value of approximately 4 to 4.5 (Figure 5E). The Kd value of
the [AZI_WT]-AZ complex was approximately 0.02 mM, 10-fold
smaller than that of [ODC_WT]-AZ. For [AZI_K125N]-AZ and
[AZI_K140M]-AZ, the Kd values were approximately 0.16 and
0.11 mM, respectively, five- to eight-fold larger than that of the
[AZI_WT]-AZ heterodimer, suggesting that these two AZI
mutant enzymes had a lower binding affinities for AZ. The
double mutant AZI_K125N/K140M had an AZ-binding affinity
similar to that of AZI_K125N, with a Kd value of 0.18 mM, nine-
fold larger than that of AZI_WT and close to the Kd value of
ODC_WT, suggesting that AZI_K125N/K140M had an AZ-
binding affinity lower than that of AZI_WT and similar to that of
ODC. Thus, the efficiency of AZI_K125N/K140M in the rescue
of the ODC enzyme activity was less than that of AZI_WT
(Figure 4C).
Solvent accessibility in the putative AZ-binding site of
ODC and AZI
Using the structures of ODC and AZI, the solvent accessibility
of the putative AZ-binding site was analyzed (http://www.ebi.ac.
uk/msd-srv/prot_int/pistart.html, [50]). Based on the values of
the accessible and buried surface areas for the residues 117 to 140,
these residues were divided into three groups. For ODC, ten
residues are totally exposed to solvent (Tyr122, Ala124, Asn125,
Asn126, Gly127, Gln129, Met130, Thr132, Phe133, and Met140),
nine of them are partially exposed to solvent (Val117, Ser118,
Gln119, Lys121, Asp134, Ser135, Glu136, Val137 and Glu138),
and five of them are totally buried in the protein (Ile120, Ala123,
Val128, Met131, and Leu139). However, there are some
differences in AZI. For AZI, fifteen residues are totally exposed
to solvent (Val117, Lys121, Tyr122, Ala124, Lys125, Val126,
Figure 4. Rescue of AZ-mediated inhibition of the activity of
ODC by wild-type and mutant AZI. ODC (20 mg/mL) was
preincubated with AZ (30 mg/mL) and then treated with various
concentrations of AZI. Open circles: AZI_WT; closed circles: mutant
AZI. (A) AZI_K125N. (B) AZI_ K140M. (C) AZI_K125N/K140M. The molar
ratio of AZ monomer versus ODC monomer was fixed at 3.5.
doi:10.1371/journal.pone.0019253.g004
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Glu138 and Lys140), four of them are partially exposed to solvent
(Ser118, Gln119, Asn135, and Ile137) and five of them are totally
buried in the protein (Ile120, Ala123, Val128, Met131, and
Leu139). Analysis of these two proteins suggested that the putative
AZ-binding site of AZI is more solvent-accessible than that of
ODC. Docking structures of mouse AZ-ODC and AZ-AZI suggest
that AZ is bound within a large groove of ODC and AZI [49].
Residues 125 and 140 in ODC and AZI are solvent-accessible and
are present on the outer part of the large groove (Figure 1, B and
C, respectively), suggesting that these two residues may directly
participate in the interaction with AZ.
Differences in the electrostatic surface drive the
differential AZ-Binding affinities of ODC and AZI
Our data clearly indicate that residues 125 and 140 play critical
roles governing the differential AZ-binding affinities of human
ODC and AZI. According to the docking result of AZ-AZI model
Figure 5. Continuous sedimentation coefficient distribution of human ODC and AZI in the presence of AZ. The concentration of ODC or
AZI was fixed at 0.3 mg/mL with four concentrations of AZ at 0.015, 0.03, 0.06, or 0.09 mg/mL (the molar ratios of AZ/ODC were 0.12, 0.24, 0.47 and
0.73). The sedimentation velocity data were globally fitted with SEDPHAT to acquire the Kd values of the ODC-AZ and AZI-AZ complexes (Table 2).
(A) ODC_WT. (B) ODC_N125K. (C) ODC_M140K. (D) ODC_N125K/M140K. (E) AZI_WT. (F) AZI_K125N. (G) AZI_ K140M. (H) AZI_K125N/K140M.
doi:10.1371/journal.pone.0019253.g005
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while in ODC a Ser is present at this position. In addition, residues
125 and 140, which are both Lys in AZI, and Asn and Met,
respectively, in human ODC are both acidic residues in
trypanosome ODC. This is important as trypanosome ODC does
not bind AZ. Thus, Lys125 and Lys140 in the putative AZ-binding
site of AZI may have electrostatic effects in the binding of AZ.
Substituting Lys for Asn125 and Met140 in ODC (ODC_N125K/
M140K) introduces extra charges into the AZ-binding element of
ODC making this region more similar to that in AZI, thus making
the ODC enzyme to more susceptible to inhibition by AZ and
more resistant to rescue by AZI. Because Lys125 and Lys140 are
of AZI conserved among different species and because in most
ODC enzymes, residue 125 is Asn or Ser and residue 140 is Met,
we believe that these two positively charged lysine residues are
important for tight binding between AZI and AZ.
In summary, according to the mutagenesis analysis and
sequence comparisons, we suggest that electrostatic effects are
responsible for the differential binding affinities between AZ and
ODC and between AZ and AZI. The results observed for
ODC_N125K/M140K and AZI_K125N/K140M support this
conclusion. The differences in these two residues between ODC
and AZI are responsible for the differential AZ-binding affinities.
Materials and Methods
Site-directed mutagenesis of the putative AZ-binding site
of ODC and AZI
Mutated human ODC and AZI plasmids were generated by
site-directed mutagenesis using the QuikChange
TM kit (Strata-
gene, USA). In the PCR reaction, purified human ODC and AZI
DNAs were used as the templates, and the high-fidelity Pfu DNA
polymerase and the specific primers with desired codons were used
to produce the specific mutated DNA. The lengths of the primers
with the preferred mutation site were designed between 25 to 45
bases; this number of bases is required for specific binding to the
template DNA. After 16–18 temperature cycles, the mutated
plasmids with staggered nicks were made. The wild-type human
ODC and AZI templates in the PCR products were cleaved by
treating with DpnI. The nicked DNAs with specific mutations
were used to transform the XL-1 E. coli strain, and the DNA
sequences were confirmed by autosequencing.
Expression and purification of recombinant ODC, AZ and
AZI
Human ODC, AZ and AZI genes were sub-cloned into the
pQE30 vector (Qiagen, Hilden, Germany) with an N-terminal
His6?Tag sequence, which is required for protein purification. The
expression vector, containing an ampicillin resistance gene, was
transformed into the JM109 strain of Escherichia coli, which was
then exposed to 1.0 mM isopropyl-1-thio-b-D-galactoside (IPTG)
to induce protein expression. The overexpressed His6?Tag
proteins were purified using Ni-NTA Sepharose (Sigma). The
lysate-Ni-NTA mixture was first washed with buffer containing
10 mM imidazole, 500 mM NaCl and 30 mM Tris-HCl (pH 7.6)
to eliminate most of the unwanted proteins. Subsequently, ODC,
AZ or AZI was eluted using elution buffer, which contained
250 mM imidazole, 500 mM NaCl, 2 mM b-mercaptoethanol
and 30 mM Tris-HCl (pH 7.6). The purified ODC or AZI was
buffer-exchanged and concentrated with 30 mM Tris-HCl
(pH 7.6) and 2 mM b-mercaptoethanol, and the purified AZ
protein was buffer-exchanged and concentrated with 250 mM
NaCl, 30 mM Tris-HCl (pH 7.6), and 2 mM b-mercaptoethanol.
The protein purity was assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and the protein
concentrations were estimated using the Bradford method [51].
ODC enzyme reaction
The ODC enzyme activity was determined using the CO2-L3K
assay kit (DCL, Charlottetown, Canada) at 37uC. The continuous
measurement of ODC enzyme activity was combined with the
phosphoenolpyruvate carboxylase- and malate dehydrogenase-
catalyzed reactions; the protocol is described in our recent paper
[29]. The reaction cocktail for the spectrophotometric assay of
ODC activity comprised 30 mM Tris-HCl (pH 7.8), 10 mM
ornithine, 0.2 mM PLP, and 0.4 mL of CO2-L3K assay buffer in a
total volume of 0.5 mL. In this coupled assay reaction, 1 mol of
CO2 was produced concomitant with the oxidation of 1 mol of
NADH analog, and the decrease in absorbance at 405 nm
corresponding to the oxidation of the NADH analog was
continuously traced using a Perkin-Elmer Lambda-25 spectropho-
tometer. An extinction coefficient of 2410 M
21 was used for the
NADH analog in these calculations. Sigma Plot 10.0 (Jandel, San
Rafael, CA) was used to carry out all of the calculations. In the
ODC inhibition experiment, the concentration of ODC was fixed
(20 mg/mL), and the AZ concentration was varied. For the AZI
rescue experiment, ODC (20 mg/mL) was first preincubated with
AZ (30–34 mg/mL) to inhibit 80% of the enzyme activity, and
then the mixture was treated with various concentrations of AZI.
The molar ratio of ODC versus AZ was calculated using the
molecular weights of monomeric ODC and AZ.
Size-distribution analysis by analytical ultracentrifugation
A Beckman Optima XL-A analytical ultracentrifuge device was
used to perform the sedimentation velocity experiments. Buffer
(400 ml) and sample solutions (380 ml) were loaded into the double
sector centerpiece separately and established in a Beckman An-50
Ti rotor. A rotor speed of 42,000 rpm was used in the
sedimentation velocity experiments. Protein samples were ana-
lyzed using UV absorbance at 280 nm in continuous mode with a
time interval of 420 s and a step size of 0.002 cm. Numerous scans
at different collecting times were fitted to a continuous size
distribution model using SEDFIT software [52,53]. All size
distributions were estimated at a confidence level of p=0.95, a
best fit average anhydrous frictional ratio (f/f0), and a resolution N
of 250 sedimentation coefficients between 0.1 and 15.0 S.
The dissociation constants (Kd) of the ODC-AZ and AZI-AZ
complexes were estimated using the results of the sedimentation
velocity experiments, which were done using a constant concen-
tration of human ODC or AZI with four different concentrations
of AZ. All sedimentation data were globally fitted into the AB
hetero-association model using SEDPHAT [54,55] to obtain the
Table 2. Dissociation constants of human ODC-AZ and AZI-
AZ complexes.
[ODC-AZ] complex Kd,ODC-AZ (mM) [AZI-AZ] complex Kd,AZI-AZ (mM)
ODC_WT 0.2160.001 AZI_WT 0.0260.009
ODC_N125K 0.1060.001 AZI_K125N 0.1660.009
ODC_M140K 0.1460.001 AZI_K140M 0.1160.001
ODC_N125K/M140K 0.0260.002 AZI_K125N/K140M 0.1860.01
The dissociation constants (Kd) of ODC-AZ and AZI-AZ were derived from the
global fitting of the sedimentation velocity data to the model of A+B«AB
hetero-association in the SEDPHAT program.
doi:10.1371/journal.pone.0019253.t002
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specific volumes of the proteins, the solvent densities, and the
viscosity were calculated using SEDNTERP [56].
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